Advanced Oncotherapy appoints Richard Amos as medical physics director
Developer of next-generation proton therapy systems for cancer treatment, Advanced Oncotherapy, announced on Tuesday that it has appointed Richard Amos as international director of medical physics, a non-board position, with effect from 1 November.
Advanced Oncotherapy
1.92p
17:30 03/05/24
FTSE AIM All-Share
729.38
16:54 14/11/24
Health Care Equipment & Services
10,406.99
16:38 14/11/24
The AIM-traded firm said Amos was joining from University College London Hospitals NHS Trust, where he was operational lead for proton therapy physics at the Department of Radiotherapy Physics.
It said he is also an honorary senior lecturer at the Department of Medical Physics and Biomedical Engineering at University College London.
“Richard is highly regarded in his field and has had 19 peer-reviewed journal articles published. He has also had 74 abstracts printed and is a regular reviewer and editor of medical journals,” Advanced Oncotherapy’s board said in a statement,
He holds a BSc (Hons) in Applied Physics from the University of Coventry and an MSc in Applied Radiation Physics from the University of Birmingham, where he was awarded the European Social Fund Graduate Scholarship.
Commenting, Richard Amos said: "My main research interests centre on the clinical implementation of Proton Beam Therapy ('PBT'), with a major focus being on developing treatment planning techniques to treat the current UK indication list for PBT and to investigate the potential of PBT for other indications, particularly left-sided breast cancer.
“I am also interested in investigating methods of optimising PBT plan robustness and minimising uncertainties associated with proton beam delivery.”
Amos said the development of “novel imaging techniques” to monitor and verify proton dose delivery in vivo is one of his main areas of expertise.
“The technical advantages of AVO'S LIGHT Accelerator promise unique opportunities to enhance the precision and adaptive characteristics of PBT.”